eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | glucosephosphate dehydrogenase deficiency |
| Comorbidity | C0002878|haemolytic anaemia |
| Sentences | 5 |
| PubMedID- 25943156 | Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (g6pd) with acute haemolytic anaemia. |
| PubMedID- 26303162 | Background: primaquine is used to prevent plasmodium vivax relapse; however, it is not implemented in many malaria-endemic countries, including cambodia, for fear of precipitating primaquine-induced acute haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency (g6pdd). |
| PubMedID- 22607348 | Primaquine has been associated with acute haemolytic anaemia in patients with g6pd deficiency and, therefore, knowledge of the prevalence and geographical distribution of this inherited blood condition in p. vivax endemic areas is important [49]. |
| PubMedID- 25885097 | Being aware of primaquine inducing acute haemolytic anaemia, participants with g6pd deficiency were exempted from taking part in a study that used primaquine to radically clear malaria parasites [13]. |
| PubMedID- 25234071 | Acute haemolytic anaemia and myolysis due to g6pd deficiency. |
Page: 1